It’s catchy Alzheimer’s?

Dec 21, 2017 | | Say something

It’s catchy Alzheimer’s? ;

Man sneezing Alzheimer no SPREAD: While abnormal proteins of Alzheimer’s disease spread from cell to cell, are not “infectious”. Check out the facts

PHILADELPHIA -. Growing evidence shows that pathological proteins linked to the onset and progression of neurodegenerative diseases are able to spread from cell to cell inside the brains of those affected and thereby “spreading” disease in a region of interconnected brain to another . A thorough study found no evidence to support the concern that these proteins are abnormal “infectious” or transmitted from animals to humans or from one person to another disease. The study by researchers from the School of Medicine Perelman at the University of Pennsylvania in collaboration with experts from the Centers for Disease Control and the Department of Health and Human Services , appears online in Archives of Neurology .

Related images
pathological deposits of Alzheimer’s disease-associated proteins and Parkinson’s disease (arrows) in samples of human pituitaries. (A = AB, the main component of plaques associated with Alzheimer’s disease, B = Tau, the main component of tangles associated with Alzheimer’s disease, C = alpha-synuclein, the major component of Lewy bodies in Parkinson’s disease)

cell-to-cell transmission is a potentially common route for spread of the disease and progression of diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) and frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS) and other related disorders. It seems that misfolded proteins spread from one cell to another and that the affected neurons become dysfunctional, while these toxic proteins are damaging other brain regions over time.

Related Post:   Treatment of chest acne, scars, pimples, and Beats

“When interrogating a existing database with information on a cohort of well-characterized patients, we were able to determine that there is no evidence suggesting that the pathology of Alzheimer’s disease or Parkinson’s disease can be transmitted between humans” he said lead author John Q. Trojanowski, MD, PhD professor Pathology and Laboratory Medicine and co-director of Penn Center Neurodegenerative Disease research . “Now we can redouble efforts to find treatments through immunotherapies or other approaches to stop the spread of these toxic proteins between cells.”

In order to verify whether such proteins potentially could lead from person to person, the team of researchers analyzed data from a cohort of existing patients who had received human growth hormone (hGH) glands pituitary of corpses through a national program, as a beneficial treatment for growth retardation before the synthetic hGH was available. About 7,700 patients were treated with the body-derived hGH (c-hGH) in the USA between 1963 and 1985. In the mid-1980s, more than 200 patients worldwide who received c-hGH inadvertently contaminated with prion proteins from pituitary tissue donor infected went on to develop an acquired form of Creutzfeldt-Jakob (CJD), an invariably fatal brain caused by pathological prion proteins are also the cause of mad cow disease rare disorder, degenerative. Since then, the cohort has been followed to keep track of all cases additional CJD, with extensive clinical records of patients older than 30 years since the therapy c-hGH stopped after the link to CJD was discovered in 1985.

Related Post:   The CTE dementia, unlike Alzheimer's disease, can be diagnosed definitively

in this study, the researchers looked for signs of an increased risk of AD, PD, FTLD or ALS among this group and found that none of the receptor c-hGH developed AD, PD or FTLD. The team identified three cases of ALS of uncertain significance, since no trace of protein disease ALS (TDP-43, FUS and ubiquilin) ​​were found in human pituitary glands, despite the presence of pathological AD (tau, Aß) and PD (alpha-synuclein) proteins. This clarified that c-hGH receptors were likely exposed to these proteins linked to neurodegenerative diseases AD, PD and FTLD but this did not result in the transmission of disease from person to person.

“This cohort is a very valuable resource and should continue to be observed, especially as rapidly increase our understanding of disease progression in neurodegenerative diseases,” said David Irwin, MD, lead author and his partner at the Center for neurodegenerative Disease Research and the department of neurology at the Perelman School of Medicine.

Further information:

The other co-authors of this study are Joseph Y. Abrams, Lawrence B. Schonberger, Ellen W. Leschek James L. Mills, yVirginia M.-Y. Leeward. This research was supported by grants from National laInstituto on Aging (AG010124 P30 Core Center Alzheimersubvención, T32-AG000255), Intramural Research Program and NacionalInstituto Child Health and Development in Nacionalesde health institutes.

Medicine Penn is one of the leading academic medical centers around the world dedicated to the related missions of medical education , biomedical research, and excellence in patient care. Penn Medicine consists of the School of Raymond and Ruth Perelman of Medicine, University of Pennsylvania (founded in 1765 as the first medical school in the nation) and University of Pennsylvania Health System , which together form a joint $ 4.3 billion.

The Perelman School of Medicine is currently ranked # 2 in US News & World Report survey of medical schools oriented research. School is consistently among the main recipients of the nation of funding from the National Institutes of Health, with $ 479.3 million awarded in fiscal year 2011.

University facilities patient care of Pennsylvania Health System includes: the Hospital of the University of Pennsylvania – recognized as one of the best hospitals in the “List of Honor” USA News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Penn Medicine also includes additional care facilities patients and services throughout the Philadelphia region

Penn Medicine is committed to improving lives and health through a variety of programs and community-based activities. In fiscal year 2011, Penn Medicine provided $ 854 million to benefit our community


Related Post:   I could fight Alzheimer extract cocoa?

This article was originally published on alzheimersweekly, Read the original article here

You may also like:

Posted in: Alzheimer's & Dementia, Caregiving, Prevention, Research, Understanding Dementia

Leave a Reply

Your email address will not be published. Required fields are marked *

==[Click 2x to Close X]==
Most Popular Today!

Sorry. No data so far.